Evidence reviewed: 8 November 2026. Alzheimer’s disease is a progressive brain disorder associated with changes in memory, thinking, language and eventually everyday function. Early symptoms often involve difficulty learning or remembering new information, but not every episode of forgetfulness means Alzheimer’s. Assessment matters because treatable conditions can resemble cognitive decline, and specialized testing and treatments have changed substantially. In particular, 2025 diagnostic guidance addresses validated Alzheimer blood biomarkers, while anti-amyloid therapies such as lecanemab and donanemab are available for selected people with early symptomatic disease in some countries [1–4].
What happens in Alzheimer’s disease?
Alzheimer pathology is associated with extracellular accumulation of amyloid-beta and abnormal accumulation of tau inside neurons, alongside loss of synaptic connections, inflammation and neuronal injury. These processes can begin years before noticeable symptoms. A person’s risk is influenced by age, genetics, cardiovascular health and other factors, but a family history is not required and the disease cannot be predicted with certainty from one risk factor [1,2].
Alzheimer’s is not the same as all dementia. Dementia describes a syndrome affecting independence; Alzheimer’s is one of its most common underlying diseases. People may have biological Alzheimer pathology while still having no functional impairment, or have symptoms caused by a different dementia subtype.
10 early warning signs worth discussing with a clinician
- Repeatedly forgetting newly learned information, asking the same questions, or needing frequent reminders beyond one’s usual pattern.
- Difficulty planning or solving familiar problems, including managing bills, recipes or appointments.
- Problems completing familiar activities, such as using appliances or following a usual route.
- Disorientation in time or place, getting lost in familiar surroundings or confusing recent events.
- Changes in visuospatial abilities, including judging distances or interpreting visual information not explained by an eye disorder.
- Word-finding or conversation difficulties, such as losing the thread of discussion or using an unusual substitute word.
- Misplacing items in unusual places and being unable to retrace steps, especially when this happens repeatedly.
- Reduced judgment, including susceptibility to scams or poor financial decisions.
- Withdrawal from usual work, hobbies or social activities because tasks have become harder.
- Noticeable changes in mood, personality or initiative that cannot easily be explained by an acute stressor.
These signs are reasons for assessment, not a diagnosis. Several can occur in depression, sleep disorders, medication effects, anxiety or another neurological condition. Sometimes the first symptoms are language- or visual-predominant rather than memory-predominant [1,2].
Normal aging, mild cognitive impairment and dementia
| Situation | Typical distinguishing feature |
|---|---|
| Normal aging | Occasional name or word retrieval difficulty while independence and familiar activities remain intact. |
| Mild cognitive impairment (MCI) | Objective cognitive decline beyond expectations, but independence in everyday activities is substantially preserved. |
| Mild Alzheimer’s dementia | Cognitive decline interferes with some daily tasks, even though a person may still perform many activities independently with assistance. |
| Moderate or severe dementia | Increasing support needs in basic and instrumental activities of daily living. |
MCI is not synonymous with Alzheimer’s disease. Some individuals with MCI have underlying Alzheimer pathology, while others have vascular, mood, medication-related or other causes. Some remain stable or improve; progression is not inevitable [1].
When should someone seek medical evaluation?
Arrange an appointment when memory or other thinking problems become persistent, progressively more noticeable or interfere with usual activities, especially if a family member or colleague also observes changes. Seek an urgent assessment for abrupt severe confusion, rapid decline over days or weeks, altered consciousness, new weakness, seizures or sudden speech problems. Acute delirium, stroke, infection or metabolic emergencies can require immediate treatment and should not be labeled ordinary Alzheimer’s progression.
How is an early Alzheimer assessment performed?
Evaluation combines the patient’s history and the observations of someone who knows them well, with consent, followed by a cognitive examination and assessment of daily functioning. Clinicians consider medicines with an anticholinergic burden, sleep disorders, depression, alcohol exposure, hearing or vision impairment and other potential explanations. Common tests may include blood count, electrolytes, thyroid function and vitamin B12, as clinically indicated [1].
Brief cognitive instruments such as the MoCA or MMSE may be used, but a score alone cannot diagnose Alzheimer’s. Age, education, language, hearing, vision and cultural context affect interpretation. A structural MRI or CT scan can help identify strokes, tumors, hydrocephalus or characteristic atrophy patterns, but hippocampal shrinkage on MRI alone is not proof of Alzheimer’s [1].
Do blood tests now diagnose Alzheimer’s disease?
In selected patients, validated blood-based tests can provide important evidence of Alzheimer-related pathology. Research has focused on plasma phosphorylated tau (especially p-tau217) and amyloid-beta ratios, among other markers. However, different laboratories and assays have different performance characteristics.
The 2025 Alzheimer’s Association clinical practice guideline applies specifically to people with objective cognitive impairment undergoing evaluation in specialized memory-care settings. It states that tests achieving at least 90% sensitivity and 75% specificity may be used to help triage patients, while tests achieving at least 90% sensitivity and 90% specificity may be used as alternatives to amyloid PET or CSF tests in specified diagnostic pathways [3].
Important limitation: Many commercial blood biomarkers do not meet these thresholds. The guideline does not recommend an indiscriminate blood test for everyone who occasionally forgets a name, nor does it allow a blood result to replace a careful clinical assessment. Positive results must be interpreted in light of the likelihood of Alzheimer pathology and the test’s validated accuracy [3].
What other tests may confirm Alzheimer pathology?
Specialists may use amyloid PET imaging or cerebrospinal fluid (CSF) biomarkers, including amyloid-beta and tau-related measures, to support diagnosis and assess eligibility for certain treatments. Tau PET or other imaging may be relevant in particular circumstances. These tests are not required for every patient with memory symptoms and should be chosen based on the clinical question and local availability.
Testing may be especially important before considering a drug that specifically targets amyloid-beta. Confirmed amyloid pathology is required before initiating current US anti-amyloid therapies. Genetic testing for inherited forms of Alzheimer’s is reserved for particular histories and requires appropriate counseling; routine consumer genetic testing is not a substitute for diagnosis [3,4].
What treatments are available?
Symptomatic medicines
For appropriate patients with mild to moderate Alzheimer’s dementia, NICE recommends donepezil, rivastigmine or galantamine, which inhibit acetylcholinesterase and can provide modest symptomatic cognitive or functional benefit. Memantine, an NMDA-receptor antagonist, is used in selected moderate or severe Alzheimer’s dementia, alone or with a cholinesterase inhibitor depending on circumstances [1].
These drugs do not remove amyloid pathology or cure Alzheimer’s. Common cholinesterase-inhibitor adverse effects include nausea, diarrhea, weight loss, slow heart rate and fainting; memantine may cause dizziness or headache. Medication choice and follow-up should consider age, heart rhythm, kidney function, co-prescribed medicines and treatment goals.
MCI alone is not an automatic indication for donepezil or memantine. The original article described starting donepezil for ‘prodromal’ Alzheimer disease without appropriate clinical qualifications; treatment depends on the established diagnosis and applicable guideline.
Anti-amyloid antibodies: lecanemab and donanemab
The US Food and Drug Administration has authorized lecanemab (Leqembi) and donanemab (Kisunla) for Alzheimer’s disease, with treatment initiated in mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia, the populations studied in clinical trials. These antibodies target amyloid-beta and can slow the rate of decline in selected patients but do not restore lost cognition or cure the disease. In some jurisdictions they are unavailable, not reimbursed or restricted by local regulatory decisions [4,5].
Such treatment requires a specialist pathway with amyloid confirmation, careful evaluation of baseline brain MRI, bleeding risks and other clinical exclusions, discussion of APOE ε4 genotype-related risk when appropriate, and serial MRI monitoring. One major risk is amyloid-related imaging abnormalities (ARIA), which can include swelling (ARIA-E) or microhemorrhage and other bleeding (ARIA-H). Although often asymptomatic, serious and sometimes fatal complications are possible [4,5].
The FDA issued additional earlier MRI monitoring recommendations in 2025 for lecanemab because ARIA can occur during initial treatment. Patients and caregivers need counseling about new headache, confusion, visual changes, weakness or seizures, and treatment centers must be equipped to identify and manage complications [4]. Anti-amyloid drugs are not appropriate for all people with memory problems or for advanced dementia.
What about lifestyle and ‘brain supplements’?
Physical activity, cardiovascular risk management, sufficient sleep, social connection, treatment of hearing loss when indicated, and smoking avoidance can support overall health and may lower some dementia risk at a population level. However, there is no evidence that turmeric, high-dose vitamin E, ginkgo, coconut oil or a particular diet cures Alzheimer’s disease. NICE recommends against offering vitamin E supplements, ginseng or herbal products to treat dementia [1].
For those already living with cognitive changes, a predictable routine, suitable activity, medication support, environmental adaptations and caregiver education can help maintain everyday participation and safety.
Practical steps after an early diagnosis
- Ask what diagnosis is established: MCI, dementia syndrome or biologically supported Alzheimer disease.
- Review reversible contributors: sleep, mood, medication effects, B12, thyroid and vascular risk.
- Discuss available treatment options, the expected degree of benefit, risks, cost and local eligibility.
- Plan ahead while preserving autonomy: finances, driving review, medication systems and advance care discussions as appropriate.
- Engage support: cognitive-stimulation programmes, occupational therapy and caregiver support services.
- Arrange follow-up for cognition, function, behavior, mood, safety and medicine tolerance.
Common questions
Is forgetting names a sign of Alzheimer’s?
Occasional name retrieval problems are common. Persistent progressive difficulties with new learning or daily functioning warrant assessment, but are not diagnostic on their own.
Can MRI confirm Alzheimer’s by showing hippocampal atrophy?
No. MRI helps identify patterns and alternative causes, but atrophy alone is nonspecific [1].
Can a blood test replace a memory-clinic evaluation?
No. Certain highly accurate biomarkers may support specialized diagnosis, but clinical assessment remains essential [3].
Do lecanemab or donanemab cure Alzheimer’s?
No. They may modestly slow progression in eligible early symptomatic disease, while introducing important monitoring and ARIA risks [4,5].
Should everyone with mild cognitive impairment start donepezil?
No. MCI has several causes, and symptomatic dementia medication is not automatically indicated simply because someone has an MCI label [1].
Can Alzheimer’s disease be prevented?
No strategy guarantees prevention. Managing vascular risk, exercise, hearing, sleep, smoking and general health is sensible, but should not be marketed as a proven cure.
Key takeaways
Early signs deserve assessment, not self-diagnosis. Distinguish MCI from dementia, rule out treatable contributors, use validated biomarkers only in appropriate clinical settings, and discuss both conventional symptomatic care and carefully selected anti-amyloid treatments with realistic expectations.
References
- National Institute for Health and Care Excellence. Dementia: assessment, management and support (NG97). Last reviewed 24 Oct 2025.
- National Institute on Aging. What is Alzheimer’s disease? NIH; accessed 8 Nov 2026.
- Alzheimer’s Association. Clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimers Dement. 2025. doi:10.1002/alz.70535. PubMed.
- US Food and Drug Administration. FDA recommends additional earlier MRI monitoring for patients taking Leqembi (lecanemab). 2025.
- US Food and Drug Administration. FDA approves Kisunla (donanemab) for Alzheimer’s disease. July 2024.
Medical disclaimer: Educational information, not a personal diagnosis. Biomarker tests and anti-amyloid therapies require specialist assessment and monitoring; approvals and access differ by region. Acute confusion, sudden weakness, severe headaches or neurological changes require urgent assessment.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.